Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors
AssigneeAnji Pharmaceuticals Inc.
InventorsKeith R. Walley, John H. Boyd, James A. Russell
Life of this patent
Estimating the term…
Abstract
There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
Claims14
A method of treating sepsis or septic shock in a subject who has sepsis or septic shock, the method comprising:
- administering an effective amount of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to the subject, wherein the PCSK9 inhibitor is selected from AMG145, 1D05-IgG2, SAR236553/REGN727 (Alirocumab), RN-316, and RG7652.
2-10. (canceled)
(canceled)
15-64. (canceled)
Dependencies are inferred from the claim text.